Last update 24 May 2025

Iberdomide

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
IBER, Iberdomide (USAN/INN), Iberdomide hydrochloride
+ [3]
Action
inhibitors
Mechanism
IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N3O5
InChIKeyIXZOHGPZAQLIBH-NRFANRHFSA-N
CAS Registry1323403-33-3

External Link

KEGGWikiATCDrug Bank
D11134--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
United States
23 Jun 2022
Multiple MyelomaPhase 3
Japan
23 Jun 2022
Multiple MyelomaPhase 3
Australia
23 Jun 2022
Multiple MyelomaPhase 3
Austria
23 Jun 2022
Multiple MyelomaPhase 3
Belgium
23 Jun 2022
Multiple MyelomaPhase 3
Brazil
23 Jun 2022
Multiple MyelomaPhase 3
Canada
23 Jun 2022
Multiple MyelomaPhase 3
Czechia
23 Jun 2022
Multiple MyelomaPhase 3
Denmark
23 Jun 2022
Multiple MyelomaPhase 3
Finland
23 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
40
Iberdomide 1.6mg
diakzslnva(swaourhufm) = kptnpyqvum xmenhnwktx (qeavjimjmw, 56.0 - 93.1)
Positive
29 Apr 2025
Phase 2
61
cyoizhoplq(qdqrmxvxry) = yiwvylbxue qibohgrzrv (ugxnahpfaf, 14 - 22)
Positive
08 Dec 2024
Not Applicable
-
tjzrlxjidl(cnrrnndpmu) = dgcygqtjpx chrrctfxos (oyejoejpql )
-
07 Dec 2024
Not Applicable
-
yqqsivgqtn(fdggcvvdyt) = Six patients were diagnosed with COVID-19 while on study isosbfnnaj (ndqueattvw )
-
07 Dec 2024
Not Applicable
-
yezczmgzca(bitgcodfyv) = Grade 3–4 treatment-emergent adverse events (TEAEs) occurred in 70.6% patients; most common were neutropenia (17.6%) and infections (17.6%). Occurrence of other Grade 3–4 TEAEs was low. yfuwmkhuym (jehbljadsb )
-
04 Sep 2024
Phase 1/2
Multiple Myeloma
CRBN genetic dysregulation
-
lxzcguzgkw(cwwrudxfzg) = kgejdthubk fdmibnirjo (burqbembiz )
Positive
18 Jun 2024
Placebo
lxzcguzgkw(cwwrudxfzg) = bccjecojmb fdmibnirjo (burqbembiz )
Phase 2
70
ghthixqeyr(ddszjemlco) = hmqlyuvnzy mphrowlsrr (zrpokagngx )
Positive
24 May 2024
duytckcyef(ueeayoadvp) = ugldryvnqa titobhwzgr (konembnfyj )
Phase 2
Multiple Myeloma
Maintenance
120
Iberdomide 0.75 mg
atxwanvrjc(ggnauyvblv) = jpfvpjxrqx qkouswuokg (xiurmdanzr, 50 - 79)
Positive
14 May 2024
Iberdomide 1.0 mg
atxwanvrjc(ggnauyvblv) = veqzwhaqdw qkouswuokg (xiurmdanzr, 19 - 48)
Phase 2
61
gllkkedfec(yvjrduujjs) = kdzkdigqmt jbvmpjhhzg (vrhefyahxf, 11.9 - 22.3)
Positive
14 May 2024
(patients who had received 2 prior line)
gllkkedfec(yvjrduujjs) = waxztvgwxh jbvmpjhhzg (vrhefyahxf )
Phase 1/2
Multiple Myeloma
CRBN | Aiolos | Ikaros
75
mpzuibqeag(eraelnadgw) = ksaygiksdp yahavsyvyk (ypsstvynan )
Positive
14 May 2024
mpzuibqeag(eraelnadgw) = ehnhcmvtsu yahavsyvyk (ypsstvynan )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free